AFP and neoplasm: Sorafenib, an AFP level of ≥400 ng/mL, the presence of EHS, the presence of Vp4 (portal vein invasion in the main trunk), tumor size ≥5 cm, and age ≥65 years were poor prognostic factors in patients with major PVTT-HCC.